TRAIL, a tumor necrosis factor-related apoptosis-inducing ligand is a member of the tumor necrosis factor (TNF) superfamily, which is a cytokine that has shown a particularly precise and selective affinity towards death receptors that are overexpressed in cancer cells. While leaving the normal cells intact and unharmed, due to this property it has been the ligand of choice for highly precise cancer chemotherapeutic delivery system development. On numerous occasions, TRAIL has been used singularly and in combination with other drugs. It was observed that TRAIL had a tendency to be susceptible in terms of the cancer cells developing resistance against it. So TRAIL monotherapy was a bit of a rough patch for the molecule to become successful in the chemotherapy universe, however the conjugations and synergistic actions of TRAIL opened up new horizons which are discussed in this review with specific interest on colorectal cancer (CRC).

中文翻译：

---

结直肠癌靶向治疗的“TRAIL”

TRAIL 是一种肿瘤坏死因子相关的凋亡诱导配体，是肿瘤坏死因子 (TNF) 超家族的成员，它是一种细胞因子，对癌细胞中过度表达的死亡受体表现出特别精确和选择性的亲和力。在保持正常细胞完好无损的同时，由于这一特性，它已成为高度精确的癌症化学治疗递送系统开发的首选配体。在许多情况下，TRAIL 被单独使用或与其他药物联合使用。据观察，TRAIL 在癌细胞对它产生耐药性方面具有易感性。所以 TRAIL 单一疗法对于分子在化疗领域取得成功来说有点艰难，